文献速递重症综合管理与镇静镇痛消化、代谢与肾脏急症

转录组内分型与蛋白生物标志物在脓毒症相关急性肾损伤风险分层中的互补作用

Complementary role of transcriptomic endotyping and protein-based biomarkers for risk stratification in sepsis-associated acute kidney injury.
PubMed 文献 · Crit Care · 2025-03-26
一句话结论在脓毒症相关急性肾损伤中,转录组内分型联合蛋白生物标志物可提高风险分层准确性,内分型+bio-ADM 的 AUC 达 0.80。

该研究为 PredARRT-Sep-Trial 的二次分析,纳入 167 例符合 Sepsis-3 标准的危重患者,按全血基因表达分类器分为炎症型(IE,33%)、适应型(AE,42%)和凝血型(CE,24%)。主要终点为肾脏替代治疗或死亡,IE 组达标率 30%,高于 AE 组 17% 和 CE 组 10%。NGAL 和 suPAR 在 IE 组不成比例升高,bio-ADM 是 CE 组最强结局预测因子;内分型联合 bio-ADM 的 AUC 为 0.80(95% CI 0.72-0.88),联合 suPAR 的 AUC 为 0.85(95% CI 0.78-0.93)。作者认为联合策略可改善 SA-AKI 风险分层,未来需进一步验证并探索治疗应用。

要点

  • 167 例 Sepsis-3 患者中,转录组内分型为 IE 者占 33%、AE 占 42%、CE 占 24%,IE 组疾病严重程度最高。
  • 主要终点(肾脏替代治疗或死亡)达标率:IE 组 30%,AE 组 17%,CE 组 10%。
  • NGAL 和 suPAR 在 IE 组不成比例升高,提示该内分型以先天免疫失调为主。
  • bio-ADM 是 CE 组最强结局预测因子;内分型+bio-ADM 的 AUC 为 0.80(95% CI 0.72-0.88)。
  • 内分型+suPAR 的 AUC 为 0.85(95% CI 0.78-0.93),联合功能与非功能生物标志物尤其改善死亡相关风险分层。

适用人群与场景

  • PredARRT-Sep-Trial 二次分析纳入的 167 例符合 Sepsis-3 标准的危重患者。

诊断标准与关键阈值

  • 采用经验证的全血基因表达分类器将患者分为三种转录组内分型:炎症型(IE)、适应型(AE)和凝血型(CE)。

研究设计与关键结果

  • 研究类型为 PredARRT-Sep-Trial 的二次分析,样本量 167 例,人群为符合 Sepsis-3 标准的危重患者。
  • 内分型分布:IE 占 33%,AE 占 42%,CE 占 24%。
  • 主要终点为肾脏替代治疗或死亡,IE 组达标率 30%,AE 组 17%,CE 组 10%。
  • 肾功能生物标志物在所有内分型中随 AKI 严重程度逐步升高;非功能生物标志物 NGAL、suPAR 和 bio-ADM 表现出独立于 AKI 严重程度的内分型特异性差异。
  • NGAL 和 suPAR 在 IE 组不成比例升高;bio-ADM 是 CE 组最强结局预测因子。
  • 内分型联合蛋白生物标志物提高主要终点和 7 天死亡的预测准确性:内分型+bio-ADM 的 AUC 为 0.80(95% CI 0.72-0.88),内分型+suPAR 的 AUC 为 0.85(95% CI 0.78-0.93)。
  • 内分型联合功能与非功能生物标志物尤其改善死亡相关风险分层。

证据类型、等级与局限

  • 证据类型:PredARRT-Sep-Trial 的二次分析。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,将转录组内分型与蛋白生物标志物谱联合可增强 SA-AKI 的风险分层,为未来个体化治疗和试验富集提供有前景的策略。
  • 作者指出,进一步研究应验证这些发现并探索治疗应用。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Sepsis-associated acute kidney injury (SA-AKI) is a prevalent and severe complication in critically ill patients. However, diagnostic and therapeutic advancements have been hindered by the biological heterogeneity underlying the disease. Both transcriptomic endotyping and biomarker profiling have been proposed individually to identify molecular subtypes of sepsis and may enhance risk stratification. This study aimed to evaluate the utility of combining transcriptomic endotyping with protein-based biomarkers for improving risk stratification in SA-AKI.

METHODS: This secondary analysis of the PredARRT-Sep-Trial included 167 critically ill patients who met Sepsis-3 criteria. Patients were stratified into three transcriptomic endotypes-inflammopathic (IE), adaptive (AE), and coagulopathic (CE)-using a validated whole-blood gene expression classifier. Eight protein-based biomarkers encompassing kidney function, vascular integrity, and immune response were measured. Predictive performance for the primary endpoint kidney replacement therapy or death was assessed using receiver operating characteristic curve analysis and logistic regression models.

RESULTS: Stratification into transcriptomic endotypes assigned 33% of patients to IE, 42% to AE, and 24% to CE. Patients classified as IE exhibited the highest disease severity and were most likely to meet the primary endpoint (30%), compared to AE and CE (17% and 10%, respectively). Kidney function biomarkers showed stepwise increases with AKI severity across all endotypes, whereas non-functional biomarkers (neutrophil gelatinase-associated lipocalin [NGAL], soluble urokinase plasminogen activator receptor [suPAR], and bioactive adrenomedullin [bio-ADM]) exhibited endotype-specific differences independent of AKI severity. NGAL and suPAR levels were disproportionately elevated in the IE group, suggesting a dominant role of innate immune dysregulation in this endotype. In contrast, bio-ADM, a marker of endothelial dysfunction, was the strongest risk-predictor of outcomes in CE. The combination of transcriptomic endotyping with protein-based biomarkers enhanced predictive accuracy for the primary endpoint and 7-day mortality, with the highest area under the receiver operating characteristic curve of 0.80 (95% CI 0.72-0.88) for endotyping + bio-ADM and 0.85 (95% CI 0.78-0.93) for endotyping and suPAR, respectively. Combinations of endotyping with functional and non-functional biomarkers particularly improved mortality-related risk stratification.

CONCLUSIONS: Combining transcriptomic endotyping with protein-based biomarker profiling enhances risk-stratification in SA-AKI, offering a promising strategy for personalized treatment and trial enrichment in the future. Further research should validate these findings and explore therapeutic applications.

来源:Crit Care,查看原文。版权归原作者所有。

参考来源

  1. Tavris BS, Morath C, Rupp C, et al. Complementary role of transcriptomic endotyping and protein-based biomarkers for risk stratification in sepsis-associated acute kidney injury. Crit Care. 2025. PMID: 40140945. doi:10.1186/s13054-025-05361-3

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。